常见变异对2型糖尿病患者磺脲类药物反应的影响：一项初步药物遗传学研究。
Effects of the and common variant on sulfonylurea response in type 2 diabetes mellitus patients: a preliminary pharmacogenetic study.
作者信息
Dianatshoar Diba, Alidaee Tara, Sarhangi Negar, Afshari Mahdi, Aghaei Meybodi Hamid Reza, Hasanzad Mandana
机构信息
Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
J Diabetes Metab Disord. 2022 Jan 11;21(1):133-139. doi: 10.1007/s40200-021-00947-4. eCollection 2022 Jun.
BACKGROUND
Type 2 diabetes mellitus (T2DM) is a common chronic condition characterized by high blood glucose levels which is caused by genetic and environmental factors. Currently, pharmacogenomics (PGx) is anticipated to enable the development of personalized treatment in a wide range of health issues. Sulfonylureas (SFUs) are among the oral anti-diabetic drugs that are very popular due to their low cost. Genetic variants in ) and have been reported for altered therapeutic response to sulfonylurea. The aim of the present study is to evaluate any association between common genetic variant of the and (rs7903146 and rs2237892, respectively) and the response to sulfonylurea in a group of Iranian patients for the first time.
METHODS
Genotyping was carried out in 30 T2DM patients who received sulfonylurea treatment for more than two months in addition to previous medication using the Sanger sequencing method.
RESULTS
In 30 T2DM patients who received SFUs treatment, 60%, 33.3% and 6.7% had CC, CT and TT genotypes, respectively. After treatment, adjusted fasting blood sugar (FBS) mean reduction level in CT and TT carriers was lower than CC carriers. Adjusted hemoglobin A1c (HbA1c) mean reduction level was also lower in CT and TT compared with CC carriers, but, none of these differences were statistically significant. Genotype frequencies of TT, CT and CC genotypes of rs2237892 variant of gene were 0 (0%), 3 (10%) and 27 (90%) respectively. Patients with CT and CC genotypes of rs2237892 variant had also similar changes in FBS (P=0.200) and HbA1c (P=0.436) after treatment with SFUs.
CONCLUSIONS
Genotypes of and common variant did not show any impact on the treatment response among T2DM patients receiving SFUs.
背景
2型糖尿病（T2DM）是一种常见的慢性病，其特征为血糖水平升高，由遗传和环境因素引起。目前，药物基因组学（PGx）有望在广泛的健康问题中推动个性化治疗的发展。磺脲类药物（SFUs）是口服抗糖尿病药物之一，因其成本低而非常受欢迎。已有报道称，（基因）和（基因）中的基因变异会改变对磺脲类药物的治疗反应。本研究的目的是首次评估一组伊朗患者中（基因）和（基因）的常见基因变异（分别为rs7903146和rs2237892）与对磺脲类药物反应之间的任何关联。
方法
采用桑格测序法对30例接受磺脲类药物治疗超过两个月且此前还接受过其他药物治疗的T2DM患者进行基因分型。
结果
在30例接受SFUs治疗的T2DM患者中，CC、CT和TT基因型的患者分别占60%、33.3%和6.7%。治疗后，CT和TT携带者的调整后空腹血糖（FBS）平均降低水平低于CC携带者。与CC携带者相比，CT和TT携带者的调整后糖化血红蛋白（HbA1c）平均降低水平也较低，但这些差异均无统计学意义。（基因）rs2237892变异的TT、CT和CC基因型频率分别为0（0%）、3（10%）和27（90%）。rs2237892变异的CT和CC基因型患者在接受SFUs治疗后，FBS（P = 0.200）和HbA1c（P = 0.436）的变化也相似。
结论
（基因）和（基因）的常见变异基因型对接受SFUs治疗的T2DM患者的治疗反应未显示出任何影响。
Zotero 插件